Frank  Stokes net worth and biography

Frank Stokes Biography and Net Worth

Frank Stokes has served as our Chief Financial Officer since December 2017. From January 2017 to December 2017, Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings and mergers and acquisitions transactions. Mr. Stokes holds a B.S. degree in Business Administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

What is Frank Stokes' net worth?

The estimated net worth of Frank Stokes is at least $252,199.90 as of January 12th, 2021. Mr. Stokes owns 11,386 shares of Castle Biosciences stock worth more than $252,200 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Stokes may own. Additionally, Mr. Stokes receives a salary of $849,360.00 as CFO at Castle Biosciences. Learn More about Frank Stokes' net worth.

How old is Frank Stokes?

Mr. Stokes is currently 53 years old. There are 4 older executives and no younger executives at Castle Biosciences. The oldest executive at Castle Biosciences is Mr. Tobin W. Juvenal, Chief Commercial Officer, who is 64 years old. Learn More on Frank Stokes' age.

What is Frank Stokes' salary?

As the CFO of Castle Biosciences, Inc., Mr. Stokes earns $849,360.00 per year. The highest earning executive at Castle Biosciences is Mr. Derek J. Maetzold, Founder, CEO, President & Director, who commands a salary of $1,450,000.00 per year. Learn More on Frank Stokes' salary.

How do I contact Frank Stokes?

The corporate mailing address for Mr. Stokes and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected]. Learn More on Frank Stokes' contact information.

Has Frank Stokes been buying or selling shares of Castle Biosciences?

Frank Stokes has not been actively trading shares of Castle Biosciences over the course of the past ninety days. Most recently, Frank Stokes sold 2,127 shares of the business's stock in a transaction on Wednesday, June 16th. The shares were sold at an average price of $73.07, for a transaction totalling $155,419.89. Learn More on Frank Stokes' trading history.

Who are Castle Biosciences' active insiders?

Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.

Are insiders buying or selling shares of Castle Biosciences?

During the last year, Castle Biosciences insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $69,024.00. During the last year, insiders at the sold shares 40 times. They sold a total of 247,483 shares worth more than $5,133,815.82. The most recent insider tranaction occured on March, 20th when insider Derek J Maetzold sold 2,295 shares worth more than $46,519.65. Insiders at Castle Biosciences own 7.7% of the company. Learn More about insider trades at Castle Biosciences.

Information on this page was last updated on 3/20/2024.

Frank Stokes Insider Trading History at Castle Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2021Sell2,127$73.07$155,419.89View SEC Filing Icon  
1/12/2021Sell7,500$78.14$586,050.0011,386View SEC Filing Icon  
11/13/2020Sell26,000$50.87$1,322,620.00
10/13/2020Sell13,000$54.79$712,270.0014,886View SEC Filing Icon  
9/15/2020Sell26,000$49.52$1,287,520.00
See Full Table

Frank Stokes Buying and Selling Activity at Castle Biosciences

This chart shows Frank Stokes's buying and selling at Castle Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Castle Biosciences Company Overview

Castle Biosciences logo
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $22.15
Low: $21.33
High: $22.52

50 Day Range

MA: $22.05
Low: $18.06
High: $25.30

2 Week Range

Now: $22.15
Low: $9.26
High: $26.70

Volume

380,382 shs

Average Volume

259,251 shs

Market Capitalization

$608.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9